Literature DB >> 19807571

Practical approach for using Medicare data to estimate costs for cost-effectiveness analysis.

John W Tumeh1, Susan G Moore, Rachel Shapiro, Christopher R Flowers.   

Abstract

Many methods have been used to measure costs for cost-effectiveness analysis in healthcare. A central challenge in cost estimation is determining the direct cost of medical goods and services from a societal perspective. This review applies the methodology for calculating Medicare reimbursements for physician services, hospital services and medications as a means of estimating healthcare costs from a US societal perspective. This review provides the tools and information needed to calculate direct medical costs related to in- and outpatient services provided by physicians and hospitals, as well as drug costs using Medicare reimbursement data. The data used in calculating Medicare reimbursements was obtained from the Centers for Medicare and Medicaid Services website. Methods for estimating costs for a particular service in a specific location using Medicare and Medicaid Services are described and demonstrated. A method based on Medicare data that uses the unadjusted geographic practice cost index and standard hospital base rate to estimate healthcare costs that can be generalized to the US population is described and demonstrated. This review provides cost-effectiveness analysts with the tools needed to calculate healthcare service costs for economic research. It contains links to all websites needed for obtaining Medicare and Medicaid Services data and provides a step-by-step analysis of the methodology involved in calculating costs. A practical guide for applying the methodology used by Medicare and Medicaid Services to calculate direct medical costs in order to estimate US societal costs in cost-effectiveness analysis is provided.

Entities:  

Year:  2005        PMID: 19807571     DOI: 10.1586/14737167.5.2.153

Source DB:  PubMed          Journal:  Expert Rev Pharmacoecon Outcomes Res        ISSN: 1473-7167            Impact factor:   2.217


  25 in total

1.  Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States.

Authors:  Qiushi Chen; Nitin Jain; Turgay Ayer; William G Wierda; Christopher R Flowers; Susan M O'Brien; Michael J Keating; Hagop M Kantarjian; Jagpreet Chhatwal
Journal:  J Clin Oncol       Date:  2016-11-21       Impact factor: 44.544

2.  Clinical Utility of Routine Cardiac Monitoring in Breast Cancer Patients Receiving Trastuzumab.

Authors:  Christine C Davis; Amelia Zelnak; J William Eley; Daniel A Goldstein; Jeffrey M Switchenko; Trevor McKibbin
Journal:  Ann Pharmacother       Date:  2016-06-15       Impact factor: 3.154

3.  Cost-effectiveness of a symptom management intervention: improving physical activity in older women following coronary artery bypass surgery.

Authors:  Lufei Young; Lani Zimmerman; Bunny Pozehl; Susan Barnason; Hongmei Wang
Journal:  Nurs Econ       Date:  2012 Mar-Apr       Impact factor: 1.085

4.  Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma.

Authors:  Qiushi Chen; Ashley D Staton; Turgay Ayer; Daniel A Goldstein; Jean L Koff; Christopher R Flowers
Journal:  Leuk Lymphoma       Date:  2017-10-25

5.  Cost-effectiveness of a patient navigation intervention to increase colonoscopy screening among low-income adults in New Hampshire.

Authors:  Ketra Rice; Krishna Sharma; Chunyu Li; Lynn Butterly; Joanne Gersten; Amy DeGroff
Journal:  Cancer       Date:  2018-12-12       Impact factor: 6.860

6.  First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis.

Authors:  Daniel A Goldstein; Qiushi Chen; Turgay Ayer; David H Howard; Joseph Lipscomb; Bassel F El-Rayes; Christopher R Flowers
Journal:  J Clin Oncol       Date:  2015-02-17       Impact factor: 44.544

7.  Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer.

Authors:  Daniel A Goldstein; Kavya Krishna; Christopher R Flowers; Bassel F El-Rayes; Tanios Bekaii-Saab; Anne M Noonan
Journal:  Med Oncol       Date:  2016-04-11       Impact factor: 3.064

8.  Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer.

Authors:  Daniel A Goldstein; Bilal B Ahmad; Qiushi Chen; Turgay Ayer; David H Howard; Joseph Lipscomb; Bassel F El-Rayes; Christopher R Flowers
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

9.  Comparison of conventional versus liposomal irinotecan in combination with fluorouracil for advanced pancreatic cancer: a single-institution experience.

Authors:  Justin C Tossey; Joshua Reardon; Jeffrey B VanDeusen; Anne M Noonan; Kyle Porter; Matthew J Arango
Journal:  Med Oncol       Date:  2019-09-07       Impact factor: 3.064

10.  Reducing adverse self-medication behaviors in older adults with the Next Generation Personal Education Program (PEP-NG): Design and methodology.

Authors:  Patricia J Neafsey; Elizabeth Anderson; Craig Coleman; Carolyn A Lin; Cyr E M'lan; Stephen Walsh
Journal:  Patient Prefer Adherence       Date:  2009-11-29       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.